Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 4. The Million Women Study

Journal of Family Planning and Reproductive Health Care

Volumn 38, Issue 2, 2012, Pages 102-109

  Shapiro, Samuel ^a   Farmer, Richard D T ^b   Stevenson, John C ^c   Burger, Henry G ^d   Mueck, Alfred O ^e,f  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d MONASH MEDICAL CENTRE   (Australia)

^e Jean Hailes Medical Centre for Women   (Australia)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BODY MASS; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RISK; EPIDEMIOLOGY; EXTERNAL BIAS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INCIDENCE; INTERNAL CONSISTENCY; MAMMOGRAPHY; QUESTIONNAIRE; ADVERSE EFFECTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG COMBINATION; ESTROGEN THERAPY; MIDDLE AGED; REPRODUCIBILITY; STATISTICAL BIAS; TIME; WOMEN'S HEALTH;

ESTROGEN; PROGESTERONE DERIVATIVE;

BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; PROGESTERONE CONGENERS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; WOMEN'S HEALTH;

EID: 84858389307     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1136/jfprhc-2011-100229     Document Type: Article

References (40)

1. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
2. Susser M. Causal Thinking in the Health Sciences. New York, NY: Oxford University Press, 1979.
3. US Depart of Health, Education and Welfare: Public Health Service. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service (Public Health Service Publication No. 11030). Washington, DC: US Government Printing Office, 1964.
4. Susser M. What is a cause and how do we know one? A grammar for pragmatic epidemiology. Am J Epidemiol 1991;133:635-648.
5. Collaborative Group on Hormonal factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.
6. Shapiro S, Farmer RD, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: Part 1. The Collaborative Reanalysis. J Fam Plann Reprod Health Care 2011;37:103-109.
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
9. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-115. (Pubitemid 44307491)
10. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045. (Pubitemid 351347060)
11. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-1692.
12. Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008;167:1207-1216.
13. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-587.
14. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23.
15. The Women's Health Initiative Steering Committee. Effect of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
16. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-1657.
17. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
18. Prentice RL, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167:1407-1415.
19. Shapiro S, Farmer RDT, Mueck AO, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Repred Health Care 2011;37:165-172.
20. Shapiro S, Farmer RDT, Seaman H, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 3. The Women's Health Initiative: unopposed estrogen. J Fam Plann Repred Health Care 2011;37:225-230.
21. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
22. Beral V, Banks E, Reeves G, et al. The effect of hormone therapy on breast and other cancers. In: Critchley H, Gebbie A, Beral V (eds). Menopause and Hormone Replacement. London: RCOG Press, 2004;136-150.
23. Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006;7:910-918. (Pubitemid 44615945)
24. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011;103:1-10.
25. The Million Women Study: A National Survey of Women Invited for Breast Screening. First questionnaire. http://www.millionwomenstudy.org/files/mws-web1. pdf [accessed 14 September 2011].
26. The Million Women Study: Confidential National Study of Women's Health. Second questionnaire. http://www.millionwomenstudy.org/files/mws-web2.pdf [accessed 14 September 2011].
27. Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 2010;1205:268-276.
28. Million Women Study Collaborators. Errata. Lancet 2003;362:1160.
29. Morrison AS, Brisson J, Khalid N. Breast cancer incidence and mortality in the breast cancer detection demonstration project. J Natl Cancer Inst 1988;80:1540-1547. (Pubitemid 19009650)
30. Banks E, Beral V, Cameron R, et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Res 2002;4:R1. (Pubitemid 34097556)
31. Shapiro S. The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 2004;7:3-7. (Pubitemid 38367157)
32. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269. (Pubitemid 29091853)
33. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997;127:1023-1028. (Pubitemid 27516615)
34. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003;163:2149-2153. (Pubitemid 37248779)
35. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999;91:2020-2028.
36. Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 1993;161:957-960. (Pubitemid 23333151)
37. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (Volume 72): Hormonal Contraception and Postmenopausal Hormone Therapy. Lyon, France: IARC, 1999;474-530.
38. Seeger H, Wallwiener D, Kraemer E, et al. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 2006;54:72-77.
39. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005;20:2052-2060. (Pubitemid 41418488)
40. Seeger MH. 2-Methoxyestradiol - biology and mechanism of action. Steroids 2010;75:625-631.